US/UK/Canada

Share

Contacts

  • BIOINVENT
    Sölvegatan 41 223 70 LUND
    +46 46 286 85 50
    +46 46 211 08 06
    http://www.bioinvent.com

    • Quotes

    FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development.
    Martin Welschof, CEO BioInvent International
    The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.
    Martin Welschof, CEO
    Pick a time period -
    Tags ( Active)

    BioStock: BioInvent deepens collaboration with MSD

    BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent’s anti-TNFR2 antibody BI-1910 in combination with MSD’s Keytruda in the second part of a phase I/IIa study in solid tumours. The monotherapy part of the study has been ongoing since December, and the first results are expected by year-end 2024.Read the full article at biostock.se: https://www.biostock.se/en/2024/04/bioinvent-deepens-collaboration-with-msd/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CEO comments on the study success in China

    BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer patients with non-Hodgkin’s lymphoma. BioStock reached out to BioInvent’s CEO Martin Welschof, who expects that 2024 will be a break-out year for the company, with multiple data readouts expected during the second half of the year.Read the full interview with Martin Welschof at biostock.se: https://www.biostock.se/en/2024/03/bioinvents-ceo-comments-on-the-study-success-in-china/ This is a press

    BioStock: BioInvent expects data from seven clinical studies in 2024

    BioInvent entered 2024 with a solid financial reserve of 1358 SEK million, equivalent to 132 million USD. Anticipating significant milestones, the company is poised to release data from seven clinical studies throughout the year. Thus building on the momentum generated in 2023 with progress across six clinical programmes.Read the article at biostock.se: https://www.biostock.se/en/2024/01/bioinvent-expects-data-from-seven-clinical-studies-in-2024/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CEO: “This year we made unprecedented progress”

    2023 has undoubtedly been one of the most successful for BioInvent, if not the most successful. The company’s cancer treatment pipeline currently includes five drug candidates progressing through six clinical trials – and progress has been announced in all programmes during the year. However, in the current tough market dynamics for biotech, like many other companies, BioInvent is valued under cash. BioStock contacted CEO Martin Welschof to talk about the progress during 2023 and to learn about his expectations for next year.Read the full interview with Martin Welschof at biostock.se:

    BioStock: BioInvent comments on breast cancer study progress

    BioInvent’s pipeline consists of five drug candidates advancing through six clinical trials. During the San Antonio Breast Cancer Symposium, BioInvent presented the first clinical data from one of these – the phase I/IIa trial of its second FcyRIIB-blocking antibody BI-1607. BioStock reached out to BioInvent’s Chief Medical Officer Andres McAllister for a comment.Read the article at biostock.se: https://www.biostock.se/en/2023/12/bioinvent-comments-on-breast-cancer-study-progress/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent is gearing up for clinical data presentations

    BioInvent marked a milestone in the third quarter of 2023 with the recruitment of the first patient for the BI-1808 single-agent phase IIa study. BI-1808, a potential novel checkpoint inhibitor, positions BioInvent at the forefront of harnessing the value of TNFR2 in cancer therapy. Meanwhile, the company is preparing for clinical data presentations of BI-1808 at SITC in San Diego, California and of BI-1607 at SABC in San Antonio, Texas.Read the article at biostock.se: https://www.biostock.se/en/2023/10/bioinvent-is-gearing-up-for-clinical-data-presentations/ This is a press release

    BioStock: BioInvent achieves research milestone in partnership with Exelixis

    BioInvent has achieved a research milestone in its partnership with Exelixis, focusing on the development of new antibodies for cancer therapy. This achievement unlocks a 1 million USD payment to BioInvent. The company's CEO Martin Welschof expressed satisfaction with the rapid progress of the collaboration while noting that it also serves as further validation for BioInvent's proprietary F.I.R.S.T. and n-CoDeR technologies.Read the article at biostock.se: https://www.biostock.se/en/2023/09/bioinvent-achieves-research-milestone-in-partnership-with-exelixis/ This is a press release

    BioStock: BioInvent soon has five drug candidates in six clinical studies

    BioInvent has made several advances in the second quarter of 2023, in particular with its lead drug candidate BI-1206. In addition to a strengthened pipeline, the company’s Q2 report highlights progress across the broad portfolio of drug candidates in clinical development. In the report, CEO Martin Welschof reminds that BioInvent will soon have five drug candidates in six parallel patient studies.Read the article at biostock.se: https://www.biostock.se/en/2023/09/bioinvent-soon-has-five-drug-candidates-in-six-clinical-studies/ This is a press release from BioStock - Connecting

    BioStock: BioInvent’s CMO comments on phase I/IIa data with BI-1808

    BioInvent’s phase I/IIa study with first-in-class anti-TNFR2 antibody BI-1808 in advanced malignancies has produced positive results. The strong interim safety data paves the way for the phase IIa part of the study. BioStock contacted the company’s CMO Andres McAllister to learn more.Read the interview with BioInvent's CMO Andres McAllister at biostock.se: https://www.biostock.se/en/2023/06/bioinvents-cmo-comments-on-phase-i-iia-data-with-bi-1808/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent ready for combination studies with BT-001

    BioInvent and its partner Transgene have reported positive results in the phase I/IIa study with the oncolytic virus BT-001. In 11 of the 18 included patients, the lesions were stabilised. In two patients, objective antitumour activity was also seen. This means that both partners can continue the evaluation as planned with the part of the study where BT-001 will be studied in combination with pembrolizumab.Read the article about BioInvent at biostock.se: https://www.biostock.se/en/2023/06/bioinvent-ready-for-combination-studies-with-bt-001/ This is a press release from BioStock -

    BioStock: BioInvent’s CFO on the company’s business strategy

    With a reported cash position of just over SEK 1.5 billion, BioInvent is very well-regarded compared to many life science companies of comparable size. The company’s CFO Stefan Ericsson tells BioStock what lies behind the company’s success. In particular, he highlights that the progress of the five ongoing clinical projects has increased the interest of domestic and international institutional investors.Read the full interview with Stefan Ericsson at biostock.se: https://www.biostock.se/en/2023/05/bioinvents-cfo-on-the-companys-business-strategy/ This is a press release from BioStock -

    BioStock: BioInvent reports clinical progress with BI-1206

    A fourth complete response has been observed in the phase I/II trial of BioInvent´s lead drug candidate BI-1206 in combination with rituximab in non-Hodgkin’s lymphoma. According to the company´s CEO Martin Welschof, this is very encouraging news for NHL patients who are in urgent need of improved treatment options.Read the article at biostock.se: https://www.biostock.se/en/2023/04/bioinvent-reports-clinical-progress-with-bi-1206/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CEO expects eventful 2023

    During 2022, biotech company BioInvent showed proof of attracting capital as well as new collaborations. The company also advanced several pipeline projects. BioInvent has thus entered 2023 with strong positioning, and several clinical updates are expected for the year. BioStock spoke with CEO Martin Welschof to find out what the year will mean for the company.Read the article about BioInvent at biostock.se: https://www.biostock.se/en/2023/03/bioinvents-ceo-expects-eventful-2023  This is a press release from

    BioStock: CMO gives insight on new BioInvent collaboration

    Having achieved a strong shareholder base, several important partnerships and a very successful capital raise last year, biotech company BioInvent has received yet another quality stamp. This one comes in the form of a collaboration agreement with the Leukemia & Lymphoma Society - whose blood cancer acceleration programme invests 3 MUSD in the company through a directed new issue. Going forward, BioInvent will get access to important knowledge and guidance from the patient organisation. BioStock contacted CMO Andres McAllister to get his comment.Read the article about BioInvent at biostock.

    BioStock: Regulatory success for BioInvent in the US

    The U.S. Food and Drug Administration has approved BioInvent’s Investigational New Drug application for the antibody BI-1607, which is being developed to enhance efficacy and overcome resistance to existing treatments for solid tumours. Now, the company, which has four different drug candidates in five clinical trials, can expand its ongoing phase I/IIa study of BI-1607 to also include patients in the US.Read the article at biostock.se: https://www.biostock.se/en/2022/11/regulatory-success-for-bioinvent-in-the-us/ This is a press release from BioStock - Connecting Innovation & Capital.

    BioStock: Strengthened finances and clinical progress for BioInvent in Q3

    The third quarter 2022 report released by biotech company BioInvent focuses on the strong cash position of a total of over SEK 1.6 billion, as well as the five ongoing projects in clinical development. According to CEO Martin Welshof, the company has created a solid foundation for significant upcoming clinical milestones.Read the full article at biostock.se: https://www.biostock.se/en/2022/11/strengthened-finances-and-clinical-progress-for-bioinvent-in-q3/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent reaches milestone for BI-1808

    BioInvent has completed the dose escalation part of the phase I/IIa study with the anti-TNFR2 drug candidate BI-1808. Supported by the positive safety and tolerability profile that the company has observed so far, BioInvent will also study the effect of a higher dose with BI-1808 as monotherapy. Also, the company has, in collaboration with CASI Pharmaceuticals, dosed the first patient in China for the phase I clinical trial evaluating BI-1206 for the treatment of non-Hodgkin’s lymphoma.Read the article about BioInvent at biostock.se: https://www.biostock.se/en/2022/09/bioinvent-reaches-

    BioStock: BioInvent sums up eventful Q2

    BioInvent’s report for the second quarter of 2022 breeds confidence. The Swedish pharmaceutical company entered into an option and license agreement with US based Exelixis, with an advance payment to BioInvent of 25 MUSD. During the period, the company also reported progress in its clinical projects, which now span five clinical programmes and a total of four drug candidates. In addition, the company strengthened its cash position by close to 300 million SEK through a directed share issue to foreign and Swedish investors, despite the turbulent global financial situation.Read the article at

    BioStock studio: BioInvent and CASI on their collaboration

    In a BioStock Studio exclusive, Martin Welschof, CEO of BioInvent and Wei-Wu He, Chairman and CEO of the American biopharma company CASI Pharmaceuticals, joined the programme to talk about the collaboration between the two companies around the development of drug candidate BI-1206. Among other things, they discussed the reasons behind CASI chosing to partner with BioInvent, the market potential for BI-1206 and the next clinical development step for the candidate.Watch the interview with Martin Welschof and Wei-Wu He at biostock.se: https://www.biostock.se/en/2022/06/bioinvent-and-casi-on-

    BioStock: BioInvent in new potentially lucrative license agreement

    BioInvent has entered into an option and license agreement with American Exelixis with a focus on the identification and development of new antibodies for immuno-oncology treatments. The agreement gives Exelixis the right to select up to three immuno-oncology antibodies using Bioinvent’s proprietary F.I.R.S.T. platform and n-CoDeR library. Exelixis pays 25 million USD upfront, and, if they choose to in-license a candidate, a licensing deal is triggered that includes milestone payments and royalties.Read the full article at biostock.se: https://www.biostock.se/en/2022/06/bioinvent-in-new-

    BioStock: Bioinvent shifts into higher gear

    The news of BioInvent's BI-1206 advancement to the expansion phase of the phase I/IIa study in the Non-Hodgkin's Lymphoma following an end-of-phase I meeting with the FDA, crowns an eventful spring for the company. Among other things, a milestone payment has been received from Hope Medicine following clinical advancements for an out-licensed antibody. It has also had three poster presentations at the AACR American Association for Cancer Research Annual Meeting, while a fifth development programme will soon enter the clinical phase.Read the full article about BioInvent at biostock.se:

    BioStock: BioInvent presents several projects at AACR’s annual meeting

    Between April 8 to 13, the annual meeting of the American Association for Cancer Research takes place. One of the participants is Swedish pharmaceutical company BioInvent, which will present several new data regarding the drug candidates BI-1607, BI-1808 and BT-001. The latter two are currently undergoing phase I/II studies evaluating safety and early indications of efficacy. The plan is to enroll the first patient in the clinical study with BI-1607 during the second quarter of this year.Read the full article about BioInvent at biostock.se: https://www.biostock.se/en/2022/03/bioinvent-

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe